← Leaderboards
Norah A Terrault
University Of California San Francisco
$1,592,304
Attributed
$1,592,304
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,592,304 · 3
By mechanism
U01$1,171,610 · 1
M01$420,694 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Mandana Khalili$12,345,266
- Peter G Stock$42,550,391
- Ann Petru$791,951
- Chris Freise$3,684,866
- Teresa L. Wright$3,215,991
Others in their field
Top investigators on “Chronic Disease /Disorder”
- William J. Blot · Vanderbilt University$24,199,258
- Brian E Henderson · University Of Southern California$17,045,598
- Jacqueline Jones Coalson · Southwest Foundation For Biomedical Res$13,074,524
- Harold I Feldman · University Of Pennsylvania$12,657,147
- Steven R Cummings · University Of California San Francisco$9,540,859
- John P Kinsella · University Of Colorado Denver$8,316,775
Research focus
Chronic Disease /DisorderHuman SubjectImmunotherapyHuman Therapy EvaluationClinical ResearchPatient Oriented ResearchMonoclonal AntibodyRacial /Ethnic DifferenceHepatitis CAfrican AmericanCaucasian AmericanInterferon AlphaHepatitis B Virus GroupGenetic SusceptibilityLiver Disorder ChemotherapyClinical Trial Phase IPrognosisRibavirinVirus GeneticsHepatitis BDrug ResistanceCooperative StudyCombination ChemotherapyVirus Load
Grant awards (12)
Resistance to Antiviral Therapy in Chronic Hepatitis C$100,000
U01 · FY2005 · DK
THE STUDY OF VIRAL RESISTANCE TO ANTIVIRAL THERAPY OF HEPATITIS C (VIRAHEP-C)$99,609
M01 · FY2005 · RR
The Study of Viral Resistance to Antiviral Therapy of Hepatitis C (Virahep-C)$177,364
M01 · FY2004 · RR
Resistance to Antiviral Therapy in Chronic Hepatitis C$128,835
U01 · FY2004 · DK
Hepatitis C Immune Globulin (Human), CivacirO in Liver Transplant Recipients$6,389
M01 · FY2004 · RR
Resistance to Antiviral Therapy in Chronic Hepatitis C$350,000
U01 · FY2003 · DK
Resistance to Antiviral Therapy in Chronic Hepatitis C$370,000
U01 · FY2002 · DK
Phase I human monoclonal antibodies in chronic hepatitis B infection$68,666
M01 · FY2002 · RR
Resistance to Antiviral Therapy in Chronic Hepatitis C$222,775
U01 · FY2001 · DK
Phase I human monoclonal antibodies in chronic hepatitis B infection$68,666
M01 · FY2001 · RR
Phase I human monoclonal antibodies in chronic hepatitis B infection$0
M01 · FY2001 · RR
Phase I human monoclonal antibodies in chronic hepatitis B infection$0
M01 · FY2000 · RR